Page last updated: 2024-12-06
etofamide
Description
Etofamide is a selective inhibitor of monoamine oxidase A (MAO-A) with antidepressant and anxiolytic effects. It was initially synthesized in the 1960s and studied for its potential therapeutic use in treating depression and anxiety disorders. Research has shown that etofamide effectively inhibits MAO-A, leading to an increase in the levels of neurotransmitters such as serotonin and norepinephrine, which are implicated in mood regulation. However, etofamide's clinical development was discontinued due to concerns about its potential side effects, including hepatotoxicity and interactions with other medications. Despite its limited clinical application, etofamide continues to be studied as a pharmacological tool to understand the role of MAO-A inhibition in mood disorders and as a potential lead compound for the development of novel antidepressants with improved safety profiles.'
etofamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 65718 |
| CHEMBL ID | 1788393 |
| CHEBI ID | 135692 |
| SCHEMBL ID | 1163863 |
| MeSH ID | M0055455 |
Synonyms (38)
| Synonym |
|---|
| ethylchlordiphene |
| n-(2-ethoxyethyl)-n-(p-(p-nitrophenoxy)-benzyl)dichloracetamide |
| eticlordifene |
| 2,2-dichloro-n-(2-ethoxyethyl)-n-(p-(p-nitrophenoxy)benzyl)acetamide |
| kitnosil |
| chlorophenoxamide ethyl ether |
| brn 2918322 |
| etofamidum [inn-latin] |
| acetamide, 2,2-dichloro-n-(2-ethoxyethyl)-n-((4-(4-nitrophenoxy)phenyl)methyl)- |
| 2,2-dichloro-n-(2-ethoxyethyl)-n-((p-nitrophenoxy)benzyl)-acetamide |
| acetamide, 2,2-dichloro-n-(2-ethoxyethyl)-n-(p-(p-nitrophenoxy)benzyl)- |
| etofamide |
| einecs 246-790-2 |
| k-430 |
| kitnos |
| etofamida [inn-spanish] |
| n-(2-etossietil)-n-(4-(4'-nitrofenossi)benzil)dicloroacetamide [italian] |
| etofamide [inn] |
| 25287-60-9 |
| D07355 |
| kitnos (tn) |
| etofamide (inn) |
| CHEBI:135692 |
| 2,2-dichloro-n-(2-ethoxyethyl)-n-[[4-(4-nitrophenoxy)phenyl]methyl]acetamide |
| unii-03f36jh21u |
| n-(2-etossietil)-n-(4-(4'-nitrofenossi)benzil)dicloroacetamide |
| 03f36jh21u , |
| etofamida |
| etofamidum |
| CHEMBL1788393 |
| etofamide [mart.] |
| etofamide [who-dd] |
| SCHEMBL1163863 |
| DTXSID40179926 |
| Q5404754 |
| DB13258 |
| EN300-19765938 |
| 2,2-dichloro-n-(2-ethoxyethyl)-n-{[4-(4-nitrophenoxy)phenyl]methyl}acetamide |
Drug Classes (1)
| Class | Description |
|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 27.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 27.90 (24.57) | | Research Supply Index | 2.40 (2.92) | | Research Growth Index | 4.51 (4.65) | | Search Engine Demand Index | 31.58 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 2 (25.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (12.50%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (62.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |